Abstract
The 7-year outcomes of the Placement of Aortic Transcatheter Valves 3 (PARTNER 3) trial comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in low-risk patients indicate that the narrowing difference between the two strategies reflects study design convergence rather than true clinical equivalence. Although the composite endpoint of death, stroke, and rehospitalization appeared comparable, important asymmetries persisted. Notably, approximately one quarter of patients in the SAVR group underwent concomitant coronary artery bypass grafting, whereas no patients underwent percutaneous coronary intervention, and surgical valve types were not standardized. In contrast, the incidences of valve thrombosis and paravalvular leak remained substantially higher after TAVI. Emerging trends in late mortality and crossing hazard curves further suggest potential divergence in long-term survival. Thus, the perceived equivalence of TAVI and SAVR largely reflects trial design and endpoint framing rather than durable clinical parity. Among younger patients, lifetime risk profiles differ fundamentally. As clinical enthusiasm for transcatheter therapy expands, careful interpretation grounded in valve durability, proportional hazards, and transparent analysis remains essential. Ultimately, long-term treatment standards should prioritize biological integrity over procedural convenience.